SMAGP: A promising drug target and biomarker for small cell adhesion

Target Name: SMAGP

NCBI ID: G57228

SMAGP

SMAGP: A promising drug target and biomarker for small cell adhesion

Introduction

Small cell adhesion glycoprotein (SMAGP) is a transmembrane protein that plays a critical role in the regulation of tight junctions and cell-cell adhesion. SMAGP is a member of the cadher family, which includes several other proteins involved in cell-cell adhesion, including cadherin, N-cadherin, and apical transmembrane protein-2 (CD94). SMAGP is expressed in most tissues and is involved in various physiological processes, including cell signaling, migration, and invasion.

SMAGP has also been identified as a potential drug target and biomarker. The development of SMAGP-targeted therapies has the potential to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SMAGP function and structure

SMAGP is a 21-kDa protein that consists of an N-terminus, a transmembrane domain, and an C-terminus. The N-terminus of SMAGP contains a protein-coding region that encodes the extracellular domain (ECD) of the protein. ECD includes a N-glycosylated region (NGR), which is important for SMAGP interactions with other proteins, including cadherins and integrins. The transmembrane domain (TMD) of SMAGP consists of a long alpha-helices and a short beta-sheet. The TMD is responsible for the formation of the transmembrane domain and is involved in the regulation of SMAGP's activity.

SMAGP is involved in several cellular processes, including cell adhesion, migration, and invasion. It plays a critical role in the regulation of tight junctions, which are a type of cell-cell adhesion that helps to maintain the integrity of tissues. SMAGP is also involved in the regulation of cell migration and invasion, which are essential processes for the development and progression of many diseases, including cancer.

SMAGP has also been shown to play a role in the regulation of various signaling pathways, including TGF-β signaling, Wnt signaling, and Notch signaling. TGF-β is a well-known signaling pathway that is involved in the regulation of cell growth, differentiation, and survival. Wnt signaling is a critical pathway that is involved in the regulation of cell growth and differentiation, and has been implicated in the development of many diseases, including cancer. Notch signaling is a highly conserved signaling pathway that is involved in the regulation of cell growth, differentiation, and survival.

SMAGP as a drug target

SMAGP has been identified as a potential drug target due to its involvement in various cellular processes that are involved in the development and progression of many diseases. The development of SMAGP-targeted therapies has the potential to treat a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SMAGP has been shown to play a role in the regulation of cell signaling pathways that are involved in the development and progression of many diseases. For example, SMAGP has been shown to be involved in the regulation of TGF-β signaling, which is a critical signaling pathway that is involved in the regulation of cell growth, differentiation, and survival.

SMAGP has also been shown to play a role in the regulation of cell migration and invasion, which are essential processes for the development and progression of many diseases, including cancer. The development of SMAGP-targeted therapies has the potential to treat various diseases, including cancer by inhibiting the activity of SMAGP in these processes.

SMAGP has also been shown to play a role in the regulation of cell adhesion, which is a critical process that is involved in the regulation of

Protein Name: Small Cell Adhesion Glycoprotein

Functions: May play a role in epithelial cell-cell contacts. May play a role in tumor invasiveness and metastasis formation

The "SMAGP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMAGP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets